

P159US
10/517741

PTO/SB/01A (09-04)
Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN
APPLICATION DATA SHEET (37 CFR 1.76)**

Title of Invention	METHOD AND NUCLEIC ACIDS FOR THE IMPROVED TREATMENT OF BREAST CELL PROLIFERATIVE DISORDERS
-------------------------------	---

As the below named inventor(s), I/we declare that:

This declaration is directed to:

- ☐ The attached application, or
☒ Application No. 10/517,741, filed on October 1, 2003,
☒ as amended on December 11, 2004 (if applicable);

I/we believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought;

I/we have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above;

I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application.


All statements made herein of my/own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.

FULL NAME OF INVENTOR(S)	
1-00 Inventor one: <u>John Foskens</u>	
Signature: _____	
8-00 Inventor two: <u>Nadia Harbeck</u>	
Signature: _____	
3-00 Inventor three: <u>Thomas Koenig</u>	
Signature: _____	
4-00 Inventor four: <u>Sabine Mair</u>	
Signature: _____	
<input checked="" type="checkbox"/> Additional inventors or a legal representative are being named on <u>1</u> additional form(s) attached hereto.	

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

BEST AVAILABLE COPY



PILS9US

PTO/SB/01A (09-04)
Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN
APPLICATION DATA SHEET (37 CFR 1.76)**

Title of Invention	METHOD AND NUCLEIC ACIDS FOR THE IMPROVED TREATMENT OF BREAST CELL PROLIFERATIVE DISORDERS
-----------------------	---

As the below named inventor(s), I/we declare that:

This declaration is directed to:

- ☐ The attached application, or
- ☒ Application No. 10/517,741, filed on October 1, 2003,
- ☒ as amended on December 11, 2004 (if applicable);

I/we believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought;

I/we have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above;

I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application.

All statements made herein of my/own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.

FULL NAME OF INVENTOR(S)

Inventor one: John Foekens

Signature: _____ Citizen of: NL

Inventor two: Nadia Harbeck

Signature: [Signature] Citizen of: DE

Inventor three: Thomas Koenig

Signature: _____ Citizen of: DE

Inventor four: Sabine Maier

Signature: _____ Citizen of: DE

☒ Additional inventors or a legal representative are being named on 1 additional form(s) attached hereto.

This collection of information is required by 35 U.S.C. 1115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

BEST AVAILABLE COPY



**DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN
APPLICATION DATA SHEET (37 CFR 1.76)**

Title of Invention	METHOD AND NUCLEIC ACIDS FOR THE IMPROVED TREATMENT OF BREAST CELL PROLIFERATIVE DISORDERS
-------------------------------	---

As the below named inventor(s), I/we declare that:

This declaration is directed to:

☐ The attached application, or

☒ Application No. 10/517.741, filed on October 1, 2003,

☒ as amended on December 11, 2004 (if applicable);

I/we believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought;

I/we have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above;

I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application.

All statements made herein of my/own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.

FULL NAME OF INVENTOR(S)	
Inventor one: <u>John Foekens</u>	
Signature: _____	Citizen of: <u>NL</u>
Inventor two: <u>Nadia Harbeck</u>	
Signature: _____	Citizen of: <u>DE</u>
Inventor three: <u>Thomas Koenig</u>	
Signature: <u><i>Thomas Koenig</i></u>	Citizen of: <u>DE</u>
Inventor four: <u>Sabine Maier</u>	
Signature: <u><i>Sabine Maier</i></u>	Citizen of: <u>DE</u>
<input checked="" type="checkbox"/> Additional inventors or a legal representative are being named on <u>1</u> additional form(s) attached hereto.	

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

BEST AVAILABLE COPY



Form 2, Declaration (37 CFR 1.63) for Utility or Design Application Using an Application Data Sheet (37 CFR 1.76)

FULL NAME OF INVENTOR(S)

5-0

Inventor five: John Martens

Signature: _____ Citizen of: NL

6-0

Inventor six: Fabian Model

Signature: _____ Citizen of: DE

7-0

Inventor seven: Inko Nimmrich

Signature: _____ Citizen of: DE

8-0

Inventor eight: Tamas Rujan

Signature: _____ Citizen of: DE

9-0

Inventor nine: Armin Schmitt

Signature: _____ Citizen of: DE

10-0

Inventor ten: Manfred Schmitt

Signature: _____ Citizen of: DE

11-0

Inventor eleven: Maxime P. Look

Signature: _____ Citizen of: NL

12-0

Inventor twelve: Almuth Marx

Signature: _____ Citizen of: DE

13-0

Inventor thirteen: Heinz Hoefler

Signature: _____ Citizen of: AT



2, Declaration (37 CFR 1.63) for Utility or Design Application Using an Application Data Sheet (37 CFR 1.76)

FULL NAME OF INVENTOR(S)

Inventor five: John Martens

Signature: _____ **Citizen of:** NL

Inventor six: Fabian Model

Signature: F. Model **Citizen of:** DE

Inventor seven: Inko Nimmrich

Signature: _____ **Citizen of:** DE

Inventor eight: Tamas Rujan

Signature: _____ **Citizen of:** DE

Inventor nine: Armin Schmitt

Signature: _____ **Citizen of:** DE

Inventor ten: Manfred Schmitt

Signature: _____ **Citizen of:** DE

Inventor eleven: Maxime P. Look


Signature: _____ **Citizen of:** NL

Inventor twelve: Almuth Marx

Signature: _____ **Citizen of:** DE

Inventor thirteen: Heinz Hoefler

Signature: _____ **Citizen of:** AT



2, Declaration (37 CFR 1.63) for Utility or Design Application Using an Application Data Sheet (37 CFR 1.76)

FULL NAME OF INVENTOR(S)

Inventor five: John Martens

Signature: _____ Citizen of: NL

Inventor six: Fabian Model

Signature: _____ Citizen of: DE

Inventor seven: Inko Nimmrich

Signature:  Citizen of: DE

Inventor eight: Tamas Rujan

Signature:  Citizen of: DE

Inventor nine: Armin Schmitt

Signature: _____ Citizen of: DE

Inventor ten: Manfred Schmitt

Signature: _____ Citizen of: DE

Inventor eleven: Maxime P. Look

Signature: _____ Citizen of: NL

Inventor twelve: Almuth Marx

Signature: _____ Citizen of: DE

Inventor thirteen: Heinz Hoefler

Signature: _____ Citizen of: AT



Declaration (37 CFR 1.63) for Utility or Design Application Using an Application Data Sheet (37 CFR 1.76)

FULL NAME OF INVENTOR(S)

Inventor five: John Martens

Signature: _____ Citizen of: NL

Inventor six: Fabian Model

Signature: _____ Citizen of: DE

Inventor seven: Inko Nimmrich

Signature: _____ Citizen of: DE

Inventor eight: Tamas Rujan

Signature: _____ Citizen of: DE

Inventor nine: Armin Schmitt

Signature: Armin Schmitt Citizen of: DE

Inventor ten: Manfred Schmitt

Signature: _____ Citizen of: DE

Inventor eleven: Maxime P. Look


Signature: _____ Citizen of: NL

Inventor twelve: Almuth Marx

Signature: _____ Citizen of: DE

Inventor thirteen: Heinz Hoefler

Signature: _____ Citizen of: AT



Declaration (37 CFR 1.63) for Utility or Design Application Using an Application Data Sheet (37 CFR 1.76)

FULL NAME OF INVENTOR(S)

Inventor five: John Martens

Signature: _____ Citizen of: NL

Inventor six: Fabian Model

Signature: _____ Citizen of: DE

Inventor seven: Inko Nimmrich

Signature: _____ Citizen of: DE

Inventor eight: Tamas Rujan

Signature: _____ Citizen of: DE

Inventor nine: Armin Schmitt

Signature: _____ Citizen of: DE

Inventor ten: Manfred Schmitt

Signature: Manfred Schmitt Citizen of: DE

Inventor eleven: Maxime P. Look


Signature: _____ Citizen of: NL

Inventor twelve: Almuth Marx

Signature: _____ Citizen of: DE

Inventor thirteen: Heinz Hoefler

Signature: _____ Citizen of: AT



Part 2, Declaration (37 CFR 1.63) for Utility or Design Application Using an Application Data Sheet (37 CFR 1.76)

FULL NAME OF INVENTOR(S)

Inventor five: John Martens

Signature: _____ Citizen of: NL

Inventor six: Fabian Model

Signature: _____ Citizen of: DE

Inventor seven: Inko Nimmrich

Signature: _____ Citizen of: DE

Inventor eight: Tamas Rujan

Signature: _____ Citizen of: DE

Inventor nine: Armin Schmitt

Signature: _____ Citizen of: DE

Inventor ten: Manfred Schmitt

Signature: _____ Citizen of: DE

Inventor eleven: Maxime P. Look

Signature: _____ Citizen of: NL

Inventor twelve: Almuth Marx

Signature: Almuth Marx Citizen of: DE

Inventor thirteen: Heinz Hoefler

Signature: _____ Citizen of: AT



2, Declaration (37 CFR 1.63) for Utility or Design Application Using an Application Data Sheet (37 CFR 1.76)

FULL NAME OF INVENTOR(S)

Inventor five: John Martens

Signature: _____ Citizen of: NL

Inventor six: Fabian Model

Signature: _____ Citizen of: DE

Inventor seven: Inko Nimmrich

Signature: _____ Citizen of: DE

Inventor eight: Tamas Rujan

Signature: _____ Citizen of: DE

Inventor nine: Armin Schmitt

Signature: _____ Citizen of: DE

Inventor ten: Manfred Schmitt

Signature: _____ Citizen of: DE

Inventor eleven: Maxime P. Look


Signature: _____ Citizen of: NL

Inventor twelve: Almuth Marx

Signature: _____ Citizen of: DE

Inventor thirteen: Heinz Hoefler

Signature:  _____ Citizen of: AT



P. Declaration (37 CFR 1.63) for Utility or Design Application Using an Application Data Sheet (37 CFR 1.76)

FULL NAME OF INVENTOR(S)

Inventor five: John Martens

Signature: _____ Citizen of: NL

Inventor six: Fabian Model

Signature: _____ Citizen of: DE

Inventor seven: Inko Nimmrich

Signature: _____ Citizen of: DE

Inventor eight: Tamas Rujan

Signature: _____ Citizen of: DE

Inventor nine: Armin Schmitt

Signature: _____ Citizen of: DE

Inventor ten: Manfred Schmitt

Signature: _____ Citizen of: DE

Inventor eleven: Maxime P. Look

Signature: _____ Citizen of: NL

Inventor twelve: Almuth Marx

Signature: _____ Citizen of: DE

Inventor thirteen: Heinz Hoefler

Signature: _____ Citizen of: AT



Rec'd PTO

03 JAN 2006

PTO/SB/80 (11-04)

Approved for use through 11/30/2005. OMB 0651-0035

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

POWER OF ATTORNEY TO PROSECUTE APPLICATIONS BEFORE THE USPTO

I hereby revoke all previous powers of attorney given in the application identified in the attached statement under 37 CFR 3.73(b).

I hereby appoint:

☒ Practitioners associated with the Customer Number:

22504

OR

☐ Practitioner(s) named below (if more than ten patent practitioners are to be named, then a customer number must be used):

Name	Registration Number	Name	Registration Number

as attorney(s) or agent(s) to represent the undersigned before the United States Patent and Trademark Office (USPTO) in connection with any and all patent applications assigned only to the undersigned according to the USPTO assignment records or assignment documents attached to this form in accordance with 37 CFR 3.73(b).

Please change the correspondence address for the application identified in the attached statement under 37 CFR 3.73(b) to:

☒ The address associated with Customer Number:

22504

OR

<input type="checkbox"/> Firm or Individual Name			
Address			
City	State	Zip	
Country			
Telephone	Fax		206-628-7699

Assignee Name and Address:

Epigenomics AG
Kleine Praesidentenstrasse 1
10178 Berlin, Germany

A copy of this form, together with a statement under 37 CFR 3.73(b) (Form PTO/SB/96 or equivalent) is required to be filed in each application in which this form is used. The statement under 37 CFR 3.73(b) may be completed by one of the practitioners appointed in this form if the appointed practitioner is authorized to act on behalf of the assignee, and must identify the application in which this Power of Attorney is to be filed.

SIGNATURE of Assignee of Record

The individual whose signature and title is supplied below is authorized to act on behalf of the assignee

Signature		Date	1/8/2005
Name	Dr. Kurt Berlin	Telephone	
Title	Executive Vice President & CSO	Kleine Praesidentenstr.1 • D-10178 Berlin phone: +49 30 24345-0 • fax: -555	

This collection of information is required by 37 CFR 1.31, 1.32 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/96 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)Applicant/Patent Owner: Epigenomics AGApplication No./Patent No.: 10/517,741 Filed/Issue Date: October 1, 2003Entitled: METHOD AND NUCLEIC ACIDS FOR THE IMPROVED TREATMENT OF BREAST CELL PROLIFERATIVE DISORDERSEpigenomics AG, a German corporation

(Name of Assignee)

(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of less than the entire right, title and interest.
The extent (by percentage) of its ownership interest is _____ %

in the patent application/patent identified above by virtue of either:

A. ☐ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

OR

B. ☐ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

1. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.
2. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.
3. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.☒ Copies of assignments or other documents in the chain of title are attached.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Signature

Date

Dr. Kurt Berlin

Printed or Typed Name

epigenomics AG
Kleine Präsidentenstr.1 • D-10178 Berlin Telephone Number
phone: +49 30 24345-0 • fax: -555Executive Vice President & CSO

Title

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ASSIGNMENT

WHEREAS, I, John Foekens, residing at Filosofentuin 35, Rotterdam, Netherlands NL-2908 XA; Nadia Harbeck, residing at Palnkamer-Strasse 49, Otterfing, Germany 83624; Thomas Koenig, residing at Skalitzer Strasse 18, Berlin, Germany 10999; Sabine Maier, residing at Markelstrasse 60, Berlin, Germany 12163; John Martens, residing at Schiekade 121 h, Rotterdam, Netherlands NL-3055 BK; Fabian Model, residing at Dedenzerstrasse 73, Berlin, Germany 12683; Inko Nimmrich, residing at Heinz-Kapelle-Strasse 9, Berlin, Germany 10407; Tamas Rujan, residing at Vinetastr. 7, Berlin, Germany 13189; Armin Schmitt, residing at Hortensienstrasse 29, Berlin, Germany 12203; Manfred Schmitt, residing at Hohenaschauerstrasse 10, Munich, Germany 81669; Maxime P. Look, residing at Stade de Colombes 55, VS Amsterdam, Netherlands NL-1098; Almuth Marx, residing at Wichherstrasse 45, Berlin, Germany 10439; and Heinz Hoefler, residing at Ismaningerstrasse 64, Munich, Germany 81675, (ASSIGNORS), are the inventors named in U.S. patent application No. 10/517,741 entitled METHOD AND NUCLEIC ACIDS FOR THE IMPROVED TREATMENT OF BREAST CELL PROLIFERATIVE DISORDERS; said application number was nationalized in the United States from International Application PCT/EP2003/010881 filed on October 1, 2003, further claiming priority to DE 10245779.4 filed October 1, 2002, DE 10300096.8 filed January 7, 2003 and DE 10317955.0 filed April 17, 2003;

AND, WHEREAS, Epigenomics AG, a German corporation, having administrative offices at Kleine Praesidentenstrasse 1, 10178 Berlin, Germany (hereinafter referred to as ASSIGNEE) is desirous of acquiring the entire right, title and interest in the invention described in the said application;

NOW, THEREFORE, for sufficient, good and valuable consideration, the receipt of which is hereby acknowledged, I do hereby sell, assign, and transfer unto said ASSIGNEE, my entire right, title to and interest in said application and said inventions; any patent or reissues of any patent that may be granted thereon; and any applications which are improvements thereon, continuations, continuations-in-part, substitutes, or divisions of said applications, and all foreign applications and patents on said invention(s) to be held and enjoyed by ASSIGNEE as entirely as the same would have been held and enjoyed by me had this sale, assignment, and transfer not been made, and I do hereby further agree and promise to execute all instruments and render all such assistance as ASSIGNEE may request in order to make and prosecute any and all applications on said invention(s), to enforce any and all patents on said invention(s), and to confirm in ASSIGNEE legal title to said invention(s) and all applications and patents on said invention(s), all without charge to ASSIGNEE but at no expense to me.

EXECUTED in Capelle 't d' Yssel this 28th day of July, 2005.

John Foekens

EXECUTED in _____, this _____ day of _____, 2005.

Nadia Harbeck

EXECUTED in Berlin, this 22 day of August, 2005.

Thomas Koenig

EXECUTED in Berlin, this 23 day of August, 2005.

Sabine Maier

EXECUTED in _____, this _____ day of _____, 2005.

John Martens

EXECUTED in _____, this _____ day of _____, 2005.

Fabian Model

EXECUTED in Berlin, this 22 day of August, 2005.

Inko Nimmrich

EXECUTED in Berlin, this 23 day of August, 2005.

Tamas Rujan

EXECUTED in _____, this _____ day of _____, 2005.

Nadia Harbeck :


EXECUTED in _____, this _____ day of _____, 2005.

Thomas Koenig :

EXECUTED in _____, this _____ day of _____, 2005.

Sabine Maier :

EXECUTED in Rotterdam, this 15th day of August, 2005.


John Martens :

EXECUTED in _____, this _____ day of _____, 2005.

Fabian Model :

EXECUTED in _____, this _____ day of _____, 2005.

Inko Nimmrich :

EXECUTED in _____, this _____ day of _____, 2005.

Tamas Rujan :

EXECUTED in _____, this _____ day of _____, 2005.

Nadia Harbeck

EXECUTED in _____, this _____ day of _____, 2005.

Thomas Koenig

EXECUTED in _____, this _____ day of _____, 2005.

Sabine Maier

EXECUTED in _____, this _____ day of _____, 2005.

John Martens

EXECUTED in Seattle, this 17 day of August, 2005.

F. Model
Fabian Model

EXECUTED in _____, this _____ day of _____, 2005.

Inko Nimmrich

EXECUTED in _____, this _____ day of _____, 2005.

Tamas Rujan

EXECUTED in Berlin, this 11th day of August, 2005.

Armin Schmitt
Armin Schmitt

EXECUTED in _____, this _____ day of _____, 2005.

Manfred Schmitt :

EXECUTED in _____, this _____ day of _____, 2005.

Maxime P. Look :

EXECUTED in _____, this _____ day of _____, 2005.

Almuth Marx :

EXECUTED in _____, this _____ day of _____, 2005.

Heinz Hoefler :

EXECUTED in _____, this _____ day of _____, 2005.

Armin Schmitt

EXECUTED in Manfred, this 29th day of July, 2005.

Manfred Schmitt
Manfred Schmitt

EXECUTED in _____, this _____ day of _____, 2005.

Maxime P. Look

EXECUTED in _____, this _____ day of _____, 2005.

Almuth Marx

EXECUTED in _____, this _____ day of _____, 2005.

Heinz Hoefler

EXECUTED in _____, this _____ day of _____, 2005.

Armin Schmitt

EXECUTED in _____, this _____ day of _____, 2005.

Manfred Schmitt

EXECUTED in Rotterdam, this 2nd day of August, 2005.

M. Look
Maxime P. Look

EXECUTED in _____, this _____ day of _____, 2005.

Almuth Marx

EXECUTED in _____, this _____ day of _____, 2005.

Heinz Hoefler

EXECUTED in _____, this _____ day of _____, 2005.

Armin Schmitt

EXECUTED in _____, this _____ day of _____, 2005.

Manfred Schmitt

EXECUTED in _____, this _____ day of _____, 2005.

Maxime P. Look

EXECUTED in Nürnberg, this 3rd day of September, 2005.

Almuth Marx
Almuth Marx

EXECUTED in _____, this _____ day of _____, 2005.

Heinz Hoefler

EXECUTED in _____, this _____ day of _____, 2005.

Armin Schmitt

EXECUTED in _____, this _____ day of _____, 2005.

Manfred Schmitt

EXECUTED in _____, this _____ day of _____, 2005.

Maxime P. Look

EXECUTED in _____, this _____ day of _____, 2005.

Almuth Marx

EXECUTED in Munich, this 9 day of September, 2005.

Heinz Hoefler

ASSIGNMENT

WHEREAS, I, John Foekens, residing at Filosofentuin 35, Rotterdam, Netherlands NL-2908 XA; Nadia Harbeck, residing at Palnkamer Strasse 49, Otterfing, Germany 83624; Thomas Koenig, residing at Skalitzer Strasse 18, Berlin, Germany 10999; Sabine Maier, residing at Markelstrasse 60, Berlin, Germany 12163; John Martens, residing at Schiekade 121 h, Rotterdam, Netherlands NL-3055 BK; Fabian Model, residing at Dedenzerstrasse 73, Berlin, Germany 12683; Inko Nimmrich, residing at Heinz-Kapelle-Strasse 9, Berlin, Germany 10407; Tamas Rujan, residing at Vinetastr. 7, Berlin, Germany 13189; Armin Schmitt, residing at Hortensienstrasse 29, Berlin, Germany 12203; Manfred Schmitt, residing at Hohenaschauerstrasse 10, Munich, Germany 81669; Maxime Pl Look, residing at Stade de Colombes 55, VS Amsterdam, Netherlands NL-1098; Almuth Marx, residing at Wicherstrasse 45, Berlin, Germany 10439; and Heinz Hoefler, residing at Ismaningerstrasse 64, Munich, Germany 81675, (ASSIGNORS), are the inventors named in U.S. patent application No. 10/517,741 entitled METHOD AND NUCLEIC ACIDS FOR THE IMPROVED TREATMENT OF BREAST CELL PROLIFERATIVE DISORDERS; said application number was nationalized in the United States from International Application PCT/EP2003/010881 filed on October 1, 2003, further claiming priority to DE 10245779.4 filed October 1, 2002, DE 10300096.8 filed January 7, 2003 and DE 10317955.0 filed April 17, 2003;


AND, WHEREAS, Epigenomics AG, a German corporation, having administrative offices at Kleine Praesidentenstrasse 1, 10178 Berlin, Germany (hereinafter referred to as ASSIGNEE) is desirous of acquiring the entire right, title and interest in the invention described in the said application;

NOW, THEREFORE, for sufficient, good and valuable consideration, the receipt of which is hereby acknowledged, I do hereby sell, assign, and transfer unto said ASSIGNEE, my entire right, title to and interest in said application and said inventions; any patent or reissues of any patent that may be granted thereon; and any applications which are improvements thereon, continuations, continuations-in-part, substitutes, or divisions of said applications, and all foreign applications and patents on said invention(s) to be held and enjoyed by ASSIGNEE as entirely as the same would have been held and enjoyed by me had this sale, assignment, and transfer not been made, and I do hereby further agree and promise to execute all instruments and render all such assistance as ASSIGNEE may request in order to make and prosecute any and all applications on said invention(s), to enforce any and all patents on said invention(s), and to confirm in ASSIGNEE legal title to said invention(s) and all applications and patents on said invention(s), all without charge to ASSIGNEE but at no expense to me.

EXECUTED in _____, this _____ day of _____, 2005.

John Foekens

EXECUTED in MUNICH, this 5 day of DECEMBER, 2005.


Nadia Harbeck :

EXECUTED in _____, this _____ day of _____, 2005.

Thomas Koenig :

EXECUTED in _____, this _____ day of _____, 2005.

Sabine Maier :

EXECUTED in _____, this _____ day of _____, 2005.

John Martens :

EXECUTED in _____, this _____ day of _____, 2005.

Fabian Model :

EXECUTED in _____, this _____ day of _____, 2005.

Inko Nimmrich :

EXECUTED in _____, this _____ day of _____, 2005.

Tamas Rujan :

EXECUTED in _____, this _____ day of _____, 2005.

Armin Schmitt

EXECUTED in _____, this _____ day of _____, 2005.

Manfred Schmitt

EXECUTED in _____, this _____ day of _____, 2005.

Maxime P. Look

EXECUTED in _____, this _____ day of _____, 2005.

Almuth Marx

EXECUTED in _____, this _____ day of _____, 2005.

Heinz Hoefler